89bio, Inc. (ETNB) NASDAQ
14.84
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
14.84
+0(+0.00%)
Currency In USD
| Previous Close | 14.84 |
| Open | 14.84 |
| Day High | 14.84 |
| Day Low | 14.84 |
| 52-Week High | 15.06 |
| 52-Week Low | 4.16 |
| Volume | 38.51M |
| Average Volume | 5.39M |
| Market Cap | 2.2B |
| PE | -4.02 |
| EPS | -3.69 |
| Moving Average 50 Days | 12.41 |
| Moving Average 200 Days | 9.75 |
| Change | 0 |
Data not available
89bio, Inc. Announces Agreement to be Acquired by Roche
GlobeNewswire Inc.
Sep 18, 2025 5:02 AM GMT
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total e
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 04, 2025 8:05 PM GMT
SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver a
89bio to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
May 06, 2025 8:05 PM GMT
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver an